P. Earl

发表

Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein

P. Earl, C. Broder, R. Doms, 1997, Journal of virology.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein

P. Earl, C. Broder, R. Doms, 1996, Journal of virology.

Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities

P. Earl, C. Broder, R. Doms, 1994, Journal of virology.

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

P. Earl, C. Broder, R. Doms, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys

Jerome H. Kim, B. Korber, P. Earl, 2013, Cell.

The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.

I. M. Belyakov, J. Berzofsky, P. Earl, 1998, The Journal of clinical investigation.

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

P. Earl, B. Moss, M. Robb, 2008, The Journal of infectious diseases.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

P. Earl, B. Moss, M. Robb, 2009, Vaccine.

In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity

P. Earl, B. Moss, M. Martin, 1988, Journal of virology.

Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge

Christiana N. Fogg, P. Earl, B. Moss, 2008, Journal of Virology.

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

Christiana N. Fogg, P. Earl, B. Moss, 2007, Vaccine.

Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model

P. Earl, B. Moss, S. Emerson, 2007, Journal of Virology.

T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.

P. Earl, B. Moss, B. Chesebro, 1986, Science.

Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging

P. Earl, B. Moss, T. Kristie, 2013, Virology.

Identification of Wild-Derived Inbred Mouse Strains Highly Susceptible to Monkeypox Virus Infection for Use as Small Animal Models

P. Earl, B. Moss, Jeffrey L. Americo, 2010, Journal of Virology.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, Catherine A. Cotter, 2015, Current protocols in microbiology.

Lethal Monkeypox Virus Infection of CAST/EiJ Mice Is Associated with a Deficient Gamma Interferon Response

P. Earl, B. Moss, Jeffrey L. Americo, 2012, Journal of Virology.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Jerome H. Kim, P. Earl, B. Moss, 2012, Vaccine.

and Efficacy of a DNA/MVA Vaccine but Does Not Diminish Humoral Immunity Decreases SIV-Specific Cellular Immunity Preexisting Vaccinia Virus Immunity

Rama, P. Earl, B. Moss, 2010 .

Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses.

P. Earl, B. Moss, S. Chakrabarti, 1988, Virology.

Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

P. Earl, B. Moss, S. Emerson, 2006, Proceedings of the National Academy of Sciences of the United States of America.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

P. Earl, B. Moss, P. Nigam, 2007, Virology.

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens

Jerome H. Kim, P. Earl, B. Moss, 2012, PloS one.

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

James G. Herndon, Silvija I. Staprans, David C. Montefiori, 2001, Science.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

P. Earl, B. Moss, D. Montefiori, 2007, Virology.

Preparation of cell cultures and vaccinia virus stocks.

P. Earl, B. Moss, M. Carroll, 2001, Current protocols in protein science.

Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors.

P. Earl, B. Moss, R. Compans, 1986, The EMBO journal.

One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection

P. Earl, B. Moss, N. Erez, 2021, Proceedings of the National Academy of Sciences.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.

W. Heneine, P. Earl, B. Moss, 2004, AIDS research and human retroviruses.

Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

P. Earl, B. Moss, F. Newman, 2007, Journal of Virology.

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

P. Earl, B. Moss, D. Montefiori, 2002, Vaccine.

Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

P. Earl, J. Sisler, E. Berger, 1992, Journal of Virology.

Interferon α/β Decoy Receptor Encoded by a Variant in the Dryvax Smallpox Vaccine Contributes to Virulence and Correlates with Severe Vaccine Side Effects

P. Earl, B. Moss, Catherine A. Cotter, 2022, mBio.

Enhanced Protection from SARS-CoV-2 Variants by MVA-Based Vaccines Expressing Matched or Mismatched S Proteins Administered Intranasally to hACE2 Mice

P. Earl, B. Moss, Catherine A. Cotter, 2022, bioRxiv.

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

P. Earl, B. Moss, G. Chuang, 2022, bioRxiv.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2017, Current protocols in protein science.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2017, Current protocols in molecular biology.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2015, Current protocols in microbiology.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

P. Earl, B. Moss, D. Montefiori, 2011, The Journal of infectious diseases.

Identification of the fusion peptide of primate immunodeficiency viruses.

P. Earl, F. Wong-Staal, G. Franchini, 1989, Science.

Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni)

P. Earl, B. Moss, Catherine A. Cotter, 2014, Virology.

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

P. Earl, R. Doms, B. Moss, 1990, Proceedings of the National Academy of Sciences of the United States of America.

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice.

P. Earl, B. Moss, E. Sandström, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

P. Earl, B. Moss, E. Sandström, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes

P. Earl, B. Moss, T. Fuerst, 1987, Molecular and cellular biology.

Overview of the vaccinia virus expression system.

P. Earl, B. Moss, 2001, Current protocols in protein science.

A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model.

P. Earl, B. Moss, Ian N. Moore, 2017, Virology.

Overview of the Vaccinia Virus Expression System

P. Earl, B. Moss, Bernard Moss, 2002, Current protocols in molecular biology.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus

P. Earl, B. Moss, L. Rhodes, 2008, Proceedings of the National Academy of Sciences.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, M. Carroll, 1998, Current protocols in molecular biology.

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults

P. Earl, B. Moss, M. Robb, 2015, PloS one.

Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene.

P. Earl, B. Moss, E. Jones, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV

Danielle Harvey, David Montefiori, P. Earl, 2005, Journal of acquired immune deficiency syndromes.

Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251

P. Earl, B. Moss, T. Rourke, 2003, Journal of Virology.

Different H–2 subregions influence immunization against retrovirus and immunosuppression

P. Earl, B. Moss, B. Chesebro, 1987, Nature.

Elimination of A-type inclusion formation enhances cowpox virus replication in mice: Implications for orthopoxvirus evolution

P. Earl, B. Moss, A. Weisberg, 2014, Virology.

Pentadienyl-metal-phosphine chemistry. 18. Mechanism of .eta.1-pentadienyl ligand isomerization. First structural characterization of a 3-.eta.1-pentadienyl-metal complex

P. Earl, J. Bleeke, 1989 .

Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition

R. Siliciano, P. Earl, B. Moss, 1990, The Journal of experimental medicine.

Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein

P. Earl, R. Doms, B. Moss, 1991, Journal of virology.

Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses

P. Earl, B. Moss, S. Koenig, 1991, Journal of virology.

Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus

P. Earl, B. Moss, A. Hügin, 1990, Journal of virology.

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

P. Earl, B. Moss, K. Abel, 2011, Vaccine.

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

P. Earl, B. Moss, K. Abel, 2010, Vaccine.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

P. Earl, B. Moss, M. Robb, 2016, AIDS research and human retroviruses.

Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein

P. Earl, B. Moss, Jeffrey L. Americo, 2003, Journal of Virology.

Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

P. Earl, B. Moss, A. Fauci, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

P. Earl, B. Moss, D. Montefiori, 2006, Virology.

Generation of recombinant vaccinia viruses.

P. Earl, B. Moss, M. Carroll, 2017, Current protocols in protein science.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, M. Carroll, 1998, Current protocols in molecular biology.

Recombinant vaccinia viruses

P. Earl, C. Broder, Christopher C. Broder, 1999, Molecular biotechnology.

The assembly of the HIV-1 env glycoprotein into dimers and tetramers.

P. Earl, R. Doms, B. Moss, 1991, Advances in experimental medicine and biology.

Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus

P. Earl, B. Moss, Jeffrey L. Americo, 2015, Virology.

Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses

P. Earl, B. Moss, Jeffrey L. Americo, 2020, PLoS pathogens.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins

P. Earl, B. Moss, W. Xiao, 2017, mBio.

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.

P. Earl, B. Moss, D. Montefiori, 2003, AIDS research and human retroviruses.

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

P. Earl, B. Moss, P. Jahrling, 2004, Nature.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

P. Earl, B. Moss, N. Sardesai, 2017, The Journal of infectious diseases.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

Jennifer A. Johnson, B. Korber, P. Earl, 2018, The Journal of infectious diseases.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

P. Earl, B. Moss, L. Eller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

J. Berzofsky, P. Earl, B. Moss, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment

P. Earl, B. Moss, J. Weir, 1986, Journal of virology.

Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles.

P. Earl, B. Moss, Mandal K. Singh, 2004, Vaccine.

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection

P. Earl, B. Moss, Jeffrey L. Americo, 2017, Journal of Virology.

Virulence Differences of Monkeypox Virus Clades 1, 2a and 2b.1 in a Small Animal Model

P. Earl, B. Moss, Jeffrey L. Americo, 2022, bioRxiv.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

P. Earl, M. Robb, V. Polonis, 2011, Vaccine.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

P. Earl, M. Robb, G. Ferrari, 2017, AIDS research and human retroviruses.

Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection

P. Earl, B. Moss, J. Vogt, 2009, Journal of Virology.

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.

J. Berzofsky, P. Earl, B. Moss, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome

P. Earl, B. Moss, D. Burton, 2020, Journal of Virology.

Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine

P. Earl, B. Moss, D. Montefiori, 2010, The Journal of Immunology.

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

P. Earl, B. Moss, Jeffrey L. Americo, 2017, Virology.

MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease

P. Earl, B. Moss, N. Erez, 2021, bioRxiv.

Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection

P. Earl, B. Moss, Catherine A. Cotter, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

P. Earl, M. Robb, V. Polonis, 2014, AIDS research and human retroviruses.

Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein.

P. Earl, B. Moss, F. Ennis, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

J. Berzofsky, P. Earl, B. Moss, 2008, Virology.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, Catherine A. Cotter, 1998, Current protocols in molecular biology.

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

P. Earl, B. Moss, J. Vogt, 2008, Vaccine.

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.

P. Earl, B. Moss, D. Montefiori, 2004, AIDS research and human retroviruses.

DNA Vaccine–Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination

J. Mullins, P. Earl, B. Moss, 2018, Human gene therapy.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.

P. Earl, B. Moss, B. Wahrén, 2012, Viral immunology.

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

Jerome H. Kim, P. Earl, B. Moss, 2010, PloS one.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial

P. Earl, M. Robb, E. Sandström, 2015, PloS one.

Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine

P. Earl, B. Moss, D. Montefiori, 2002, Journal of Virology.

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

P. Earl, B. Moss, M. Robb, 2009, Vaccine.

Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein

J. Berzofsky, P. Earl, B. Moss, 1998, Journal of Virology.

Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140

P. Earl, C. Broder, B. Moss, 2001, Journal of Virology.

Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers

P. Earl, R. Doms, B. Moss, 1992, Journal of Virology.

Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol

P. Earl, B. Moss, D. Montefiori, 2004, Journal of Virology.

Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines

P. Earl, B. Moss, D. Montefiori, 2002, Journal of Virology.

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.

Todd M. Allen, J. Malley, P. Earl, 2002, Virology.

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

M. Hudgens, P. Earl, B. Moss, 2012, Vaccine.

Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice

P. Earl, B. Moss, Catherine A. Cotter, 2023, npj Vaccines.

Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model

P. Earl, B. Moss, Jeffrey L. Americo, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.

P. Earl, B. Moss, 1993, AIDS research and human retroviruses.

Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface

Richard D. Leapman, P. Earl, B. Moss, 2002, Journal of Virology.

Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation

P. Earl, B. Moss, R. Leapman, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein

P. Earl, B. Moss, Jeffrey L. Americo, 2003, Journal of Virology.

Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains

P. Earl, R. Longhi, C. Ripamonti, 2005, Journal of Virology.

The Human Immunodeficiency Virus Type 1 gp120 V2 Domain Mediates gp41-Independent Intersubunit Contacts

P. Earl, B. Moss, R. Center, 2000, Journal of Virology.

A model for the involvement of the small nucleolar RNA (U3) in processing eukaryotic ribosomal RNA

P. Earl, S. Kanaya, R. Crouch, 1983, Molecular Biology Reports.

Identification, sequence, and expression of the gene encoding the second-largest subunit of the vaccinia virus DNA-dependent RNA polymerase.

P. Earl, B. Moss, M. Holmes, 1991, Virology.

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.

P. Earl, B. Moss, D. Montefiori, 2009, Vaccine.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

P. Earl, B. Moss, Catherine A. Cotter, 2017, Current protocols in protein science.

Characterization of recombinant vaccinia viruses and their products.

P. Earl, B. Moss, 1998, Current protocols in protein science.

Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus

J. Sodroski, P. Earl, B. Moss, 1999, Journal of Virology.

Immunodeficiency Virus Variants of Simian-Human Characterization of Primary Isolate-Like

Bilska, J. Sodroski, P. Earl, 1999 .

Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates

P. Earl, B. Moss, A. Otteken, 1996, Journal of virology.

Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain

P. Earl, R. Doms, B. Moss, 1990, Journal of virology.

Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques.

P. Earl, B. Moss, M. Robert-Guroff, 1989, AIDS Research and Human Retroviruses.

Control of a Mucosal Challenge and Prevention of AIDS in Rhesus Macaques by a Multiprotein DNA/MVA Vaccine

P. Earl, B. Moss, D. Montefiori, 2001 .

Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals

P. Earl, B. Moss, D. Montefiori, 2005, Virology Journal.

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge

P. Earl, N. Sullivan, A. Nasir, 2023, Science Translational Medicine.

The ectodomain of HIV‐1 env subunit gp41 forms a soluble, alpha‐helical, rod‐like oligomer in the absence of gp120 and the N‐terminal fusion peptide.

P. Earl, B. Moss, W. Weissenhorn, 1996, The EMBO journal.

P. Earl, M. Robb, E. Sandström, 2017, AIDS Research and Human Retroviruses.

P. Earl, B. Moss, D. Montefiori, 2005, Virology Journal.